Another hiv vaccine failure: Where to next?
The recent high-profile failure of an HIV vaccine trial (HVTN 505) raises some key questions for researchers in this field1. The authors tested a vaccine regimen consisting of a DNA vector encoding HIV-1 Gag, Pol, Nef and Env proteins followed by a recombinant adenovirus type 5 (rAd5) boost in an at-risk population in the US, with ˜1, 250 individuals given the vaccine and a similar number given a placebo. The vaccine did not reduce the rate of HIV-1 acquisition or the viral-load set point in the population studied. We asked four experts for their opinions on this trial and how they think the HIV field should move on from this disappointing result. © 2013 Nature America, Inc. All rights reserved.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency